ICLE 2022 | Identifying positive regulators of T cell functions to improve cellular therapies
Mateusz Legut, PhD, New York Genome Center, New York, NY, provides an overview of his research on synthetic drivers of T-cell proliferation. An analysis of the whole human genome via CRISPR revealed a number of genes, including the lymphotoxin beta receptor (LTBR) gene, are not normally expressed in T-cells. Mechanistic studies have determined the LTBR gene to improve cell quality without affecting functionality. Dr Legut additionally highlights that any new genes discovered and utilized should not pose a risk in a clinical setting and describes potential clinical trials with the enhanced T-cell therapies in patients with relapsed/refractory B-cell malignancies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
